<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02571855</url>
  </required_header>
  <id_info>
    <org_study_id>AC-078-102</org_study_id>
    <nct_id>NCT02571855</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of ACT-541468 in Healthy Young Adults and Elderly Subjects</brief_title>
  <official_title>Double-blind, Placebo-controlled, Randomized Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-541468: Part A: Multiple-ascending Doses in Healthy Young Adults After Morning Administration Part B: Single-ascending Doses in Healthy Elderly Subjects After Morning Administration Part C: Repeated Doses in Both Healthy Young Adults and Elderly Subjects After Evening Administration</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Actelion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Actelion</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the tolerability, safety, pharmacokinetics (PK, or
      amount of drug over time in the body) and pharmacodynamics (PD, or effects on the body) of
      ACT-541468 following multiple ascending doses in healthy adults and following single
      ascending doses in healthy elderly subjects when administered in the morning. The safety, PK
      and PD of ACT-541468 will also be assessed after repeated evening administration of a
      selected dose in both healthy adults and elderly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the first-in-man study, single doses of ACT-541468 administered in healthy young adults
      were well tolerated up to the dose level of 200 mg (inclusive) and yielded results compatible
      with possible sleep facilitating effects of ACT-541468. So the present study aimed to further
      investigate the effects of ACT-541468 after multiple ascending doses in healthy young
      subjects as well as after single ascending doses in elderly subjects (morning
      administrations). The effects of repeated administrations of a selected dose administered in
      the evening in both healthy adults and elderly, will also be investigated.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 1, 2015</start_date>
  <completion_date type="Actual">February 1, 2016</completion_date>
  <primary_completion_date type="Actual">February 1, 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Adverse Events (AEs)</measure>
    <time_frame>up to 72 hours post dosing</time_frame>
    <description>Treatment emergent adverse events and treatment emergent serious adverse events will be evaluated throughout the study</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in ECG variables and vital signs (heart rate and blood pressure)</measure>
    <time_frame>up to 72 hours post dosing</time_frame>
    <description>12-lead electrocardiogram variables including RR, PR, QRS, QT and QTc intervals at scheduled time points during Parts A, B and C</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes from baseline in clinical laboratory parameters</measure>
    <time_frame>up to 72 hours post dosing</time_frame>
    <description>Laboratory tests including hematology, blood chemistry and urinalysis at scheduled time points during PArts A, B and C</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) of ACT-541468 after daytime and bedtime intake</measure>
    <time_frame>Part A: Day 1 and Day 5; Part B: Day 1; Part C: evening of Day 8 (pre-dose) and Day 9 (nighttime samples)</time_frame>
    <description>Cmax will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses to identify the nighttime PK profile (Part C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (tmax) of ACT-541468 after daytime and bedtime intake</measure>
    <time_frame>Part A: Day 1 and Day 5; Part B: Day 1; Part C: evening of Day 8 (pre-dose) and Day 9 (nighttime samples)</time_frame>
    <description>tmax will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses to identify the nighttime PK profile (Part C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal half-life [t(1/2)] after daytime and bedtime intake</measure>
    <time_frame>Part A: Days 1 and 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)</time_frame>
    <description>t(1/2) will be determined after single (Parts A and B) and multiple morning doses (Part A) as well as after repeated evening doses (Part C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areas under the plasma concentration-time curves [AUC(0-8), AUC(0-24)] of ACT-541468 after daytime and bedtime intake</measure>
    <time_frame>Part A: Days 1 and 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)</time_frame>
    <description>AUC from time 0 to 8 hours after study drug administration [AUC(0--8)] and from time 0 to 24 hours after study drug administration [AUC(0--24)] will be determined after single (parts A and B) and multiple morning doses (Part A) as well as after multiple evening doses (Part C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Areas under the plasma concentration-time curves [AUC(0-t), AUC(0-inf)] of ACT-541468 after daytime and bedtime intake</measure>
    <time_frame>Part A: Day 5, from pre-dose up to 72 h post-dose; Part B: Day 1, at pre-dose up to 72 h post-dose; Part C: from the morning of Day 8 up to 60 h post-dose and from the evening of Day 8 (pre-dose) until 36 h post-dose (with nighttime samples)</time_frame>
    <description>AUC from time 0 to infinity [AUC(0--inf], AUC from time 0 to time of the last measured concentration above the limit of quantification [AUC(0--t)] will be determined after single (Part B) and multiple morning doses (Part A) as well as after multiple evening doses (Part C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sedation as measured by saccadic peak velocity</measure>
    <time_frame>Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14</time_frame>
    <description>saccadic eye movements (SEM) will be recorded by electrooculography and the average values of saccadic peak velocity of the SEM will be used as parameter of sedation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual motor coordination</measure>
    <time_frame>Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14</time_frame>
    <description>Visual motor coordination will be assessed with the adaptive tracking test and the average tracking performance will be used as parameter of coordination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in body sway</measure>
    <time_frame>Part A: Day 1 and Day 5; Part B: Day 1; Part C: Day 2 and Day 14</time_frame>
    <description>Body sway will be assessed using a body sway meter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subjective cognitive effects</measure>
    <time_frame>Part A: every day from Day 1 to Day 6; Part B: Day 1; Part C: Day 1 to Day 8</time_frame>
    <description>Subjects will rate sleepiness, alertness and mood using questionnaires</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">85</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Part A: ACT-541468 multiple ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six young adults will receive ACT-541468 in the morning from Day 1 to Day 5 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 10, 25 and 75 mg per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For each ACT-541468 dose level tested in Part A, 2 young adults will receive matching placebo in the same conditions (total number of subjects = 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: ACT-541468 single ascending doses</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Six elderly will receive ACT-541468 in the morning of Day 1 at each dose level in a sequential manner (total number of subjects = 18). Planned dose levels are 5, 15 and 25 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>For each ACT-541468 dose level tested in Part B, 2 elderly will receive matching placebo in the same conditions (total number of subjects = 6)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: repeated dose of ACT-541468</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sixteen young adults and eight elderly will receive ACT-541468 (planned dose: 25 mg) in the evening for 7 days (8 days for 6 of the 16 young adults).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Four young adults and 2 elderly will receive matching placebo in the same conditions as subjects receiving the active compound in Part C</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468 (hydrochloride salt)</intervention_name>
    <description>Hard-gelatin capsules (strength: 5 mg and 25 mg)</description>
    <arm_group_label>Part A: ACT-541468 multiple ascending doses</arm_group_label>
    <arm_group_label>Part B: ACT-541468 single ascending doses</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ACT-541468 (free base)</intervention_name>
    <description>Soft capsules (strength: 25 mg)</description>
    <arm_group_label>Part C: repeated dose of ACT-541468</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsules matching the ACT-541468 formulations</description>
    <arm_group_label>Part C: Placebo</arm_group_label>
    <arm_group_label>Part B: Placebo</arm_group_label>
    <arm_group_label>Part A: Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Adults aged from 18 to 45 years (inclusive) for Part A; elderly aged from 65 to 80
             years (inclusive) for Part B; both adults from 18 to 45 years and elderly from 65 to
             80 years (inclusive) for Part C.

          -  Regular sleep pattern of at least 6 hours nocturnal sleep.

          -  Young females must have negative pregnancy tests at screening and at pre-dose on Day 1
             and use a reliable method of contraception

          -  Body mass index (BMI) between 18.0 and 30.0 kg/m2 (inclusive) at screening.

          -  Systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse rate (PR)
             between 100-145 mmHg, 50-90 mmHg and 45-90 bpm (all inclusive) for young adults,
             respectively; SBP, DBP and PR between 100-160 mmHg, 50-95 mmHg and 45-100 bpm (all
             inclusive) for elderly, respectively.

          -  Healthy on the basis of physical examination,electrocardiogram and laboratory tests.

        Exclusion Criteria:

        Principal exclusion criteria common to young adults and elderly:

          -  Pregnant or lactating women.

          -  Any contraindication to the study drugs.

          -  History or presence of any disease or condition or treatment, which may put the
             subject at risk of participation in the study or may interfere with the absorption,
             distribution, metabolism or excretion of the study drugs.

          -  History of narcolepsy or cataplexy or modified Swiss narcolepsy scale total score &lt; 0
             at screening.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             the subject's full participation in the study or compliance with the protocol.

        Exclusion criteria for young adults only:

          -  Treatment with any prescribed medications or over-the-counter medications within 2
             weeks prior to study drug administration.

        Exclusion criteria for elderly only:

          -  Previous chronic treatment with any medication that is not given in stable doses
             and/or stable regimen within 2 months prior to screening.

          -  Previous treatment with CNS-active drugs or within 2 months prior to screening.

          -  Treatment with inhibitors of CYP3A4 (e.g., azole derivatives, ritonavir,
             clarithromycin) from 2 weeks prior to screening visit and up to EOS.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens MÃ¼hlan, MSc</last_name>
    <role>Study Director</role>
    <affiliation>Actelion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Investigator Site</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2015</study_first_submitted>
  <study_first_submitted_qc>October 7, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 8, 2015</study_first_posted>
  <last_update_submitted>July 25, 2017</last_update_submitted>
  <last_update_submitted_qc>July 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>insomnia</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Pharmacodynamics</keyword>
  <keyword>Healthy</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

